Eradication of tumors and development of anti-cancer immunity using STINGa targeted by pHLIP
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.1023959
Abstract: Despite significant progress in the development of novel STING agonists (STINGa), applications appear to be challenged by the low efficiency and poor selectivity of these agents. A pH Low Insertion Peptide (pHLIP) extends the lifetime… read more here.
Keywords: eradication tumors; ct26 tumors; development; stinga ... See more keywords